Diagnosis and therapy of cancer using sgp28-related molecules
CA 2386865 C · Owner: Agensys, Inc. · Inventors: Afar, Daniel E. H.; Raitano, Arthur B.; Hubert, Rene S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human SGP28 gene, proteins encoded by the SGP28 gene and fragments thereof, and antibodies capable of specifically recognizing and binding to SGP28 proteins.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 27, 2000 and granted May 22, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 27, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 27, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.